Sichuan Neo-life Biotech

Neo-life Biotech is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of innovative antibody-based therapeutics for oncology and autoimmune diseases. The company leverages its proprietary antibody discovery platform to engineer high-affinity monoclonal and bispecific antibodies, as well as next-generation antibody-drug conjugates (ADCs). Their lead programs focus on well-validated immune checkpoints and growth factor receptors, aiming to provide more effective treatment options for patients with refractory solid tumors. Neo-life Biotech maintains a robust R&D infrastructure and has established several strategic collaborations to accelerate its pipeline through clinical development.